Search News
-
Published on Oct 9, 2024Source: The Recorder - California - Label Pending
-
Published on 00:39 GMT
External Nasal Dilator Market to Grow by USD 242.3 Million from 2024-2028 Driven by Rising Air Pollution, with AI ...
NEW YORK, Oct. 13, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The Global External Nasal Dilator Market size is estimated to grow by USD 242.3 million from 2024-2028, according to Technavio. The market is estimated to grow at …
Source: WFMZ - Pennsylvania - Neutral -
Published on 00:39 GMT
Gastrointestinal Diseases Therapeutics Market to Grow by USD 18.5 Billion from 2024-2028 Driven by Rising Disease ...
NEW YORK, Oct. 13, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The Global Gastrointestinal Diseases Therapeutics Market size is estimated to grow by USD 18.5 billion from 2024-2028, according to Technavio. The market is …
Source: WFMZ - Pennsylvania - Neutral -
Published on Oct 13, 2024
2 Best Artificial Intelligence Stocks to Buy in October
The artificial intelligence (AI) market has created some monster growth stocks already, but companies involved in enabling this technological revolution are still seeing growing opportunities. Here are two AI leaders that could be profitable investments …
Source: Yahoo Finance - Label Pending -
Published on Oct 12, 2024
World business leaders will be served halal meat at summit to show best of British
A GATHERING to show the best of British to world business leaders has halal meat as its main menu option. The Prime Minister, Chancellor and Business Secretary are hosting the much-vaunted International Investment Summit tomorrow. 2 The Prime Minister, …
Source: The Sun - Right-wing -
Published on Oct 11, 2024
Cerebras IPO has 'too much hair' as AI chipmaker tries to sell Wall Street on Nvidia alternative
Andrew Feldman, co-founder and CEO of Cerebras Systems, speaks at the Collision conference in Toronto on June 20, 2024. Ramsey Cardy | Sportsfile | Collision | Getty Images AI chipmaker Cerebras is trying to be the first major venture-backed tech company …
Source: CNBC - Neutral -
Published on Oct 12, 2024
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Ongoing research is uncovering hidden links between rheumatology and virology. This research has become more pertinent in recent years against the background of the COVID-19 pandemic. “There is little evidence today that COVID-19, particularly as it has …
Source: HCPLive - Label Pending -
Published on Oct 11, 2024
Novel theories of harm spark legal uncertainty for pharmaceutical deal reviews
Introduction As competition authorities’ review of pharmaceutical deals continues to expand, there is ongoing attention to whether the existing toolbox for identifying and remedying competition issues suffices. For example, in March 2021, several …
Source: Global Competition Review - Label Pending -
Published on Oct 11, 2024
Gilead Sciences Stock Trades Flat; Neutral Rating by Zacks Research with $89 Price Target
Gilead Sciences Inc. (GILD), currently trading at $84.64 (at times of publication on October 11, 2024), has received a Neutral recommendation from Zacks Equity Research with a 6-12 month price target of $89.00. This marks an upgrade from a previous …
Source: Top News - Label Pending -
Published on Oct 11, 2024
Brazil: key enforcement developments amid evolving pharma landscape
In summary Brazil has seen an increase in patent litigation, as the local economy grows and stabilises. With more companies eyeing Brazil as a strategic option for the enforcement of its intellectual property rights, it is important to be aware of the …
Source: Intellectual Asset Management - Label Pending